Indeed, the neutralization of IL-1α in NMU-treated mice significantly reduced the levels of tumor areas than control group and, very importantly, NSCLC patients who presented high levels of IL-1α and caspase-4 had lower median survival rate. The gene discussed is IL1A; the disease is non-small cell lung carcinoma.